Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: A role for antiplatelet therapy?

Thorax

Volumn 69, Issue 7, 2014, Pages 609-615

  Harrison, Michelle T ^a   Short, Philip ^a,b   Williamson, Peter A ^a,c   Singanayagam, Aran ^d   Chalmers, James D ^a,b   Schembri, Stuart ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c PERTH ROYAL INFIRMARY   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; HOSPITAL PATIENT; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOSIS; TREATMENT RESPONSE; VERY ELDERLY;

AGED; ASPIRIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; THROMBOCYTOSIS; TICLOPIDINE;

EID: 84902254011     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2013-203996     Document Type: Article

References (32)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26. (Pubitemid 29054847)
3. Holguin F, Folch E, Redd SC, et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005;128:2005-11. (Pubitemid 41507534)
4. Incalzi RA, Caradonna P, Ranieri P, et al. Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir Med 2000;94:1079-84.
5. Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010;137:1091-7.
6. Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest 2005;115:3355-62. (Pubitemid 43121819)
7. Tabuchi A, Kuebler WM. Endothelium-platelet interactions in inflammatory lung disease. Vascul Pharmacol 2008;49:141-50.
8. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. Clin Invest 2005;115:3378-84. (Pubitemid 43121822)
9. McDonald TP, Cottrell M, Clift R. Effects of short-term hypoxia on platelet counts of mice. Blood 1978;51:165-75. (Pubitemid 8264127)
10. Wedzicha JA, Cotter FE, Empey DW. Platelet size in patients with chronic airflow obstruction with and without hypoxaemia. Thorax 1988;43:61-4. (Pubitemid 18031937)
11. Wedzicha JA, Syndercombe-Court D, Tan KC. Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxaemia. Thorax 1991;46:504-7.
12. Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998;31:352-8. (Pubitemid 28153455)
13. Maclay JD, McAllister DA, Johnston S, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011;66:769-74.
14. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005;128:2640-6. (Pubitemid 41507622)
15. Sidney S, Sorel M, Quesenberry CP, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005;128:2068-75.
16. Stone IS, Petersen SE, Barnes NC. Raised troponin in COPD: clinical implications and possible mechanisms. Heart 2013;99:71-2.
17. Schembri S, Williamson PA, Short PM, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 2013;346:f1235.
18. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of Chronic Obstructive Pulmonary Disease using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012;186:975-81.
19. Shorr AF, Sun X, Johannes RS, et al. Validation of a novel risk score for severity of illness in acute exacerbations of COPD. Chest 2011;140:1177-83.
20. Thompson CB, Eaton KA, Princiotta SM, et al. Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function. Br J Haematol 1982;50:509-19. (Pubitemid 12184016)
21. Roberts CM, Stone RA, Buckingham RJ, et al. National Chronic Obstructive Pulmonary Disease Resources and Outcomes Project implementation group. Acidosis, non-invasive ventilation and mortality in hospitalised COPD exacerbations. Thorax 2011;66:43-8.
22. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005;2:8-11. (Pubitemid 40562956)
23. de Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-Gonzalez-Moro JM, et al. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chron Obstruct Pulmon Dis 2012;7:679-86.
24. Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011;66:764-8.
25. Man P, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006;61:849-53. (Pubitemid 44570304)
26. Antonescu-Turcu AL, Tomic R. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. Curr Opin Pulm Med 2009;15:120-5.
27. Agustí A, Edwards LD, Rennard SI, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7:e37483.
28. Eurich DT, Marrie TJ, Johnstone J, et al. Mortality reduction with influenza vaccine in patients with pneumonia outside "flu" season: pleiotropic benefits or residual confounding? Am J Respir Crit Care Med 2008;178:527-33.
29. Short PM, Lipworth SI, Elder DH, et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011;342:d2549.
30. Rutten FH, Zuithoff NPA, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations of patients with Chronic Obstructive Pulmonary Disease. Arch Intern Med 2010;170:880-7.
31. Royal College of Physicians of London, British Thoracic Society and British Lung Foundation. Report of the National Chronic Obstructive Pulmonary Disease Audit 2008: clinical audit of COPD exacerbations admitted to acute NHS units across the UK. Nov 2008. http://www.brit-thoracic.org.uk/Portals/0/ Clinical%20Information/COPD/NCROP/NCROPClinicalAudit.pdf (accessed Jun 2013).
32. Drummond MB, Wise RA, John M, et al. Accuracy of death certificates in COPD: analysis from the TORCH trial. COPD 2010;7:179-85.